Nonischemic cardiomyopathy (NICM) is common and patients are at significant risk for early mortality secondary to ventricular arrhythmias.   In this interview, Jonathan Chrispin MD, FACC, and Dhanunjaya “DJ” Lakkireddy MBBS, FACC, discuss Risk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL    

Detecting HF (cardiac dysfunction) during pregnancy and shortly after having a baby can be challenging for health care professionals and is often delayed. The use of a device powered by artificial intelligence can assist health care providers in identifying this condition earlier.   In this interview, Demilade A. Adedinsewo MD, FACC, and Steven E. Nissen MD, MACC, discuss the AHA Late-Breaker: Screening for Peripartum Cardiomyopathies Using an Artificial Intelligence Enhanced Digital...

Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Testosterone is widely prescribed to aging men but there have been concerns about heart-related safety.  The FDA mandated that the makers of testosterone products conduct a trial to determine if these drugs increase the risk of heart attack or stroke.    In this interview, Steven E. Nissen, MD, MACC, and William E. Boden MD, FACC, discuss Cardiovascular Safety of Testosterone-Replacement Therapy.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL    

Does early ECLS improve survival in patients with AMI and cardiogenic shock? In this interview, Holger Thiele MD and Sidney C. Smith Jr. MD, MACC, discuss ESC Hot Line: ECLS-SHOCK - venoarterial membrane oxygenation in cardiogenic shock.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Colchicine did not significantly reduce the incidence of two common cardiovascular complications: Perioperative AF and myocardial injury after non-cardiac surgery (MINS).  However, there was an encouraging signal of benefit for colchicine to reduce the incidence of adverse cardiovascular outcomes in patients undergoing major noncardiac thoracic surgery, which requires further study.   In this interview, David Conen MD, MPH, and Joseph E. Marine MD, MBA, FACC discuss ESC Hot Line: COP-AF...

Contrary to findings from observational studies which are inherently affected by bias, digoxin use in randomised controlled trials (RCTs) did not lead to excess mortality in our meta-analysis of 87 studies. There is evidence that digoxin can reduce heart failure-related deaths and hospitalizations. This has implications in treating concomitant atrial fibrillation and heart failure, with two RCTs currently underway to improve our evidence base.    In this interview, Asgher Champsi MD, and...

The rates of stroke after left atrial appendage occlusion with the Watchman device in real-world clinical practice in the US is relatively low and consistent with those from clinical trials despite the high thromboembolic risk of the patients undergoing the procedure. The rates of death are relatively high in this elderly population with high rates of comorbidities, highlighting the need for shared decision-making regarding the procedure.   In this interview, James V. Freeman MD, MPH, MS,...

Currently no approved therapies exist to target obesity-related heart failure with preserved ejection fraction, a condition increasing in prevalence and associated with high symptom burden. In this interview, Mikhail Kosiborod MD, and Alison L. Bailey MD, FACC, discuss ESC Hot Line: STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Results presented at the European Society of Cardiology Congress 2023 further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular events and demonstrate particular benefit in those with diabetes. In this interview, Stephen J. Nicholls MBBS, PhD, FACC and Erin D. Michos, MD, MHS, FACC, discuss the total events analysis from the CLEAR Outcomes trial.   This ACCEL episode is part of an ACC course titled Bempedoic Acid: New Evidence Transforming the LDL-C...

What is known about the use of wearables and their impact on health outcomes and healthcare use among patients with atrial fibrillation.    In this interview, Dipak Kotecha MBChB, PhD and Sidney C. Smith Jr. MD, MACC, discuss “ESC Late-Breaker: RATE-AF trial wearables study.”   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In selected countries from each of the six WHO regions, the INTERASPIRE survey is being conducted to provide a unique picture of CHD patients, their cardiometabolic, renal and biomarker status, lifestyle and therapeutic management, and the quality of preventive care in their region. In this interview, John W. McEvoy MB, BCh, BAO, MHS, and William E. Boden MD, FACC discuss INTERASPIRE: An International Survey of Secondary Prevention of CVD. Subscribe on Apple Podcasts  Subscribe on Google...

Understanding, recognizing and effectively treating PAD has the potential to dramatically alter a patient’s life. A patient’s ability to walk, quality of life, and longevity can all be profoundly impacted.  In this interview, Sasanka Jayasuriya, MD, FACC, Douglas Weaver MD, MACC, and Sun Moon Kim MD, FSCAI, FACC, discuss Contemporary Therapy in PAD That Every Cardiologist Should Know.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Cardiorenal syndromes cause fluid retention and venous congestion that, in turn, damages the function of vital organs. Providers should have zero tolerance for excessive fluid retention. Aggressive diuretic treatment seems particularly beneficial in patients who are hospitalized for decompensated heart failure.   In this interview, Paolo Colombo MD, FACC, and William E. Boden MD, FACC, FAHA, discuss Renal Considerations in the Management of Heart Failure.  Subscribe on Apple Podcasts...

Patients with heart attacks often have a lifesaving procedure to open up the narrowed or blocked coronary artery responsible for their heart attack. In about 30-50% of these patients, additional blockages or narrowings that did not cause the heart attack are found. Evidence doesn’t support clinical decision-making on how to identify which of these additional narrowings to open or whether to open all of them.  In this interview, Shamir R. Mehta MD, MSc, FACC, and Matt Cavender MD, MPH,...

In this interview, Michael Kontos, MD, FACC, and John Gorcsan III, MD, FACC discuss High Sensitivity Troponins in Evaluation of Acute Chest Pain.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

As device therapy continues to evolve, there is an emerging opportunity to address tricuspid valve disease in patients who previously were overlooked due to their high surgical risk. Proper patient selection and medical optimization will be critical factors driving the success or failure of these nascent technologies.   In this interview, Sean Pinney MD, FACC, FAST, FHFSA, and Sidney C. Smith Jr. MD, MACC, discuss "Optimal Medical Therapy for Tricuspid Regurgitation: An Oxymoron?"  ...

In patients with heart failure, viability tests (special heart scans) allow clinicians to distinguish permanently damaged (scarred) parts of the heart from those that may be hibernating and could recover function. Following decades of use based on this theory, the utility of viability tests at predicting prognosis and recovery of heart function has been scientifically tested in the REVIVED Viability study, the results of which could dramatically change the way heart failure patients are...

HCM is present in 1 in 500 individuals around the world.  While most patients with HCM can have a normal lifestyle and longevity, there are important issues regarding family screening, sudden cardiac arrest risk, and therapies.  In this interview, Steve R. Ommen MD, FACC, and Matthew Martinez MD, FACC, discuss Hypertrophic Cardiomyopathy: Genetics, Natural History, Evolution and Septal Reduction Therapies.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Roxana Mehran MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI, and Richard A. Chazal MD, MACC, discuss The Multidisciplinary Heart Team For All: What the Revascularization Guidelines Say and How To Do It.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Millions of people are being prescribed Paxlovid for COVID-19 treatment; many of them are on cardiovascular medications. Paxlovid can have potentially harmful interactions with commonly prescribed cardiovascular medications and hence it is crucial to be aware of them and build a strategy to avoid them while providing effective treatment for COVID -19.   In this interview, Sarju Ganatra MD, FACC, and Joseph E. Marine MD, MBA, FACC, discuss Cardiovascular Drug Interactions with...

The U.S. health care sector contributes 8% to 10% of total national greenhouse gas (GHG) emissions. The harmful effects of GHG on overall public health as well as cardiovascular diseases are well documented and have been studied extensively. What do we know about cardiac interventions and their effect on global warming?   In this interview, Alison L. Bailey MD, FACC and DJ Lakkireddy MD, FACC discuss “Impact of Cardiac Interventions and Diagnostic Tests on Carbon Footprint and Potential...

The 2023 Appropriate Use Criteria for Chronic Coronary Disease are easier to navigate and less complex than prior versions. The AUC offer clinicians and patients updated clinical guidance on which tests are warranted and also when testing can be deferred.  In this interview, David E. Winchester MD, MS, FACC, and Christopher M. Kramer MD, FACC discuss Practice-Changing Recommendations from the 2023 Multimodality SIHD AUC.    Subscribe on Apple Podcasts | Subscribe on Google Play |...

Chronic kidney disease (CKD) is highly prevalent in persons with type 2 diabetes (T2D). Patients with T2D and CKD are at high cardiovascular risk. To diagnose CKD and assess risk requires measuring and monitoring kidney function by both estimated globmerular filtration rate (eGFR) and urine albumin (proteinuria) in order to deliver goal-directed therapies. SGLT2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor antagonist (MRA), along with a conventional ACE...

Shortness of breath may be due to many varied causes of which cardiac causes are important to be identified. Despite good contractile function, the heart may fail to pump properly due to impaired filling pressure leading to shortness of breath  In this interview, Abdullah Al Shafi Majumder, MD, FACC, FRCP, FESC, FASE, and Nanette Kass Wenger MD, MACC, discuss differentiating HFpEF from other causes of dyspnea.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL